Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more
Market Cap & Net Worth: Beximco Pharmaceuticals Limited (BXP)
Beximco Pharmaceuticals Limited (LSE:BXP) has a market capitalization of $2.31 Million (GBX18.96 Billion) as of March 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #43077 globally and #699 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beximco Pharmaceuticals Limited's stock price GBX42.50 by its total outstanding shares 446112089 (446.11 Million).
Beximco Pharmaceuticals Limited Market Cap History: 2015 to 2026
Beximco Pharmaceuticals Limited's market capitalization history from 2015 to 2026. Data shows growth from $767.97K to $2.31 Million (13.94% CAGR).
Beximco Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beximco Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Beximco Pharmaceuticals Limited's market cap is 0.00 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.00x
Beximco Pharmaceuticals Limited's market cap is 0.00 times its annual earnings
9.89x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $767.97K | $12.97 Billion | $1.95 Billion | 0.00x | 0.00x |
| 2016 | $1.81 Million | $13.36 Billion | $1.97 Billion | 0.00x | 0.00x |
| 2017 | $1.99 Million | $15.51 Billion | $2.23 Billion | 0.00x | 0.00x |
| 2018 | $1.56 Million | $17.72 Billion | $2.54 Billion | 0.00x | 0.00x |
| 2019 | $1.67 Million | $22.82 Billion | $3.03 Billion | 0.00x | 0.00x |
| 2020 | $4.08 Million | $25.61 Billion | $3.51 Billion | 0.00x | 0.00x |
| 2021 | $5.16 Million | $29.49 Billion | $5.13 Billion | 0.00x | 0.00x |
| 2022 | $2.42 Million | $34.67 Billion | $5.12 Billion | 0.00x | 0.00x |
| 2023 | $2.03 Million | $39.27 Billion | $4.61 Billion | 0.00x | 0.00x |
| 2024 | $2.12 Million | $44.39 Billion | $5.83 Billion | 0.00x | 0.00x |
Competitor Companies of BXP by Market Capitalization
Companies near Beximco Pharmaceuticals Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Beximco Pharmaceuticals Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Beximco Pharmaceuticals Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Beximco Pharmaceuticals Limited's market cap moved from $767.97K to $ 2.31 Million, with a yearly change of 13.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX2.31 Million | 0.00% |
| 2025 | GBX2.31 Million | +8.97% |
| 2024 | GBX2.12 Million | +4.41% |
| 2023 | GBX2.03 Million | -16.34% |
| 2022 | GBX2.42 Million | -53.02% |
| 2021 | GBX5.16 Million | +26.44% |
| 2020 | GBX4.08 Million | +144.38% |
| 2019 | GBX1.67 Million | +6.71% |
| 2018 | GBX1.56 Million | -21.35% |
| 2017 | GBX1.99 Million | +9.71% |
| 2016 | GBX1.81 Million | +136.08% |
| 2015 | GBX767.97K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Beximco Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.31 Million USD |
| MoneyControl | $2.31 Million USD |
| MarketWatch | $2.31 Million USD |
| marketcap.company | $2.31 Million USD |
| Reuters | $2.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.